uniQure Announces Enrollment of Next Two Patients in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
13 oct. 2020 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Oct. 13, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure to Participate in Multiple Upcoming Industry Conferences in October
30 sept. 2020 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Sept. 30, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces Recommendations from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
25 sept. 2020 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure to Participate in Multiple Upcoming Industry Conferences in September
03 sept. 2020 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Sept. 03, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces Appointment of Ricardo Dolmetsch, Ph.D., as President, Research & Development
26 août 2020 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Aug. 26, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...